Clinical Trial Update: A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC [NA]

View source ↗

Summary

This entry reports a real-world study evaluating pralsetinib in combination with Leucogen for RET fusion-positive non-small cell lung cancer; the study is not y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Leucogen
• Pralsetinib (pralsetinib)

Snippet

Sponsor: Fudan University | Conditions: Non-small Cell Lung Cancer, RET Fusion | NA | Status: NOT_YET_RECRUITING